CD19 and leukemia: In order to verify that substitution of an ICD from alternative CD3 chains for the canonical CD3ζ endodomain can mitigate cytokine production, we generated mesothelin- and CD19-targeted CAR-T cells, and co-cultured these cells with HeLa cells or a CD19-positive human leukemia cell line, Nalm6, respectively.